FDA approval for clinical studies is a critical regulatory milestone for biotech companies, often leading to positive investor sentiment. The clearance of Palatin Technologies' IND application for a Phase 2 study signifies a significant step forward in its product development pipeline, potentially addressing a large market in obesity treatment. This development is likely to be viewed positively by investors, potentially leading to an uptick in PTN's stock price in the short term.